Recurrence morbidity of olfactory neuroblastoma
© 2024 ARS‐AAOA, LLC..
BACKGROUND: With modern treatment paradigms, olfactory neuroblastoma (ONB) has favorable overall survival (OS); however, the incidence of recurrence remains high. The primary aims of this study were to delineate the prognosis of recurrence of ONB and explore how recurrence subsites are associated with OS, disease-specific survival (DSS), and further recurrence.
METHODS: A retrospective chart review of ONB cases from nine academic centers between 2005 and 2021 was completed. Tumor characteristics, recurrence subsites, timelines to recurrence, additional recurrences, and survival estimates were determined using descriptive and time-to-event analyses.
RESULTS: A final cohort of 233 patients was identified, with 70 (30.0%) patients recurring within 50.4 (standard deviation ±40.9) months of diagnosis on average, consisting of local (50%), neck (36%), intracranial (9%), and distant (6%) recurrence. Compared with subjects without recurrence, patients with recurrence had significantly different primary American Joint Committee on Cancer T stage (p < 0.001), overall stage (p < 0.001), and modified Kadish scores (p < 0.001). Histopathology identified that dural involvement and positive margins were significantly greater in recurrent cases. First recurrence was significantly associated with worse 5-year DSS (hazard ratio = 5.62; p = 0.003), and subjects with neck or local recurrence had a significantly better DSS compared to intracranial or distant recurrence.
CONCLUSIONS: Recurrent cases of ONB have significantly different stages and preoperative imaging factors. Patients with local or neck recurrence, however, have better DSS than those with intracranial or distant recurrence, independent of initial tumor stage or Hyams grade. Identifying specific factors that confer an increased risk of recurrence and DSS is important for patient counseling in addition to surveillance planning.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
International forum of allergy & rhinology - (2024) vom: 03. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Melder, Katie [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Esthesioneuroblastoma |
|---|
| Anmerkungen: |
Date Revised 03.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1002/alr.23351 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370573420 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370573420 | ||
| 003 | DE-627 | ||
| 005 | 20240404000835.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240404s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/alr.23351 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1363.xml |
| 035 | |a (DE-627)NLM370573420 | ||
| 035 | |a (NLM)38567900 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Melder, Katie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Recurrence morbidity of olfactory neuroblastoma |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 03.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024 ARS‐AAOA, LLC. | ||
| 520 | |a BACKGROUND: With modern treatment paradigms, olfactory neuroblastoma (ONB) has favorable overall survival (OS); however, the incidence of recurrence remains high. The primary aims of this study were to delineate the prognosis of recurrence of ONB and explore how recurrence subsites are associated with OS, disease-specific survival (DSS), and further recurrence | ||
| 520 | |a METHODS: A retrospective chart review of ONB cases from nine academic centers between 2005 and 2021 was completed. Tumor characteristics, recurrence subsites, timelines to recurrence, additional recurrences, and survival estimates were determined using descriptive and time-to-event analyses | ||
| 520 | |a RESULTS: A final cohort of 233 patients was identified, with 70 (30.0%) patients recurring within 50.4 (standard deviation ±40.9) months of diagnosis on average, consisting of local (50%), neck (36%), intracranial (9%), and distant (6%) recurrence. Compared with subjects without recurrence, patients with recurrence had significantly different primary American Joint Committee on Cancer T stage (p < 0.001), overall stage (p < 0.001), and modified Kadish scores (p < 0.001). Histopathology identified that dural involvement and positive margins were significantly greater in recurrent cases. First recurrence was significantly associated with worse 5-year DSS (hazard ratio = 5.62; p = 0.003), and subjects with neck or local recurrence had a significantly better DSS compared to intracranial or distant recurrence | ||
| 520 | |a CONCLUSIONS: Recurrent cases of ONB have significantly different stages and preoperative imaging factors. Patients with local or neck recurrence, however, have better DSS than those with intracranial or distant recurrence, independent of initial tumor stage or Hyams grade. Identifying specific factors that confer an increased risk of recurrence and DSS is important for patient counseling in addition to surveillance planning | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a esthesioneuroblastoma | |
| 650 | 4 | |a olfactory neuroblastoma | |
| 650 | 4 | |a recurrence | |
| 650 | 4 | |a sinonasal malignancy | |
| 650 | 4 | |a skull base | |
| 700 | 1 | |a Mace, Jess C |e verfasserin |4 aut | |
| 700 | 1 | |a Choby, Garret |e verfasserin |4 aut | |
| 700 | 1 | |a Almeida, Joao Paulo |e verfasserin |4 aut | |
| 700 | 1 | |a Champagne, Pierre-Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Chan, Erik |e verfasserin |4 aut | |
| 700 | 1 | |a Ciporen, Jeremy |e verfasserin |4 aut | |
| 700 | 1 | |a Chaskes, Mark B |e verfasserin |4 aut | |
| 700 | 1 | |a Fernandez-Miranda, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Fung, Nicholas K |e verfasserin |4 aut | |
| 700 | 1 | |a Gardner, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Hwang, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Ji, Keven Seung Yong |e verfasserin |4 aut | |
| 700 | 1 | |a Kalyvas, Aristotelis |e verfasserin |4 aut | |
| 700 | 1 | |a Kong, Keonho A |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Chirag |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Zara |e verfasserin |4 aut | |
| 700 | 1 | |a Celda, Maria Peris |e verfasserin |4 aut | |
| 700 | 1 | |a Pinheiro-Neto, Carlos D |e verfasserin |4 aut | |
| 700 | 1 | |a Snyderman, Carl |e verfasserin |4 aut | |
| 700 | 1 | |a Thorp, Brian D |e verfasserin |4 aut | |
| 700 | 1 | |a Van Gompel, Jamie J |e verfasserin |4 aut | |
| 700 | 1 | |a Zenonos, Georgios |e verfasserin |4 aut | |
| 700 | 1 | |a Zwagerman, Nathan T |e verfasserin |4 aut | |
| 700 | 1 | |a Sanusi, Olabisi |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Eric W |e verfasserin |4 aut | |
| 700 | 1 | |a Geltzeiler, Mathew |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International forum of allergy & rhinology |d 2011 |g (2024) vom: 03. Apr. |w (DE-627)NLM209105178 |x 2042-6984 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:03 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/alr.23351 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 03 |c 04 | ||